CN102872086A - Application of Houttuynoid A in medicines for treating skin cancer - Google Patents
Application of Houttuynoid A in medicines for treating skin cancer Download PDFInfo
- Publication number
- CN102872086A CN102872086A CN2012104185987A CN201210418598A CN102872086A CN 102872086 A CN102872086 A CN 102872086A CN 2012104185987 A CN2012104185987 A CN 2012104185987A CN 201210418598 A CN201210418598 A CN 201210418598A CN 102872086 A CN102872086 A CN 102872086A
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- medicines
- skin cancer
- application
- treating skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of Houttuynoid A in medicines for treating skin cancer, and belongs to the technical field of new applications of medicines. In vitro MTT (Methyl Thiazolyl Tetrazolium) antineoplastic activity evaluation finds that Houttuynoid A has remarkable inhibition effect on the growth of human skin cancer cell lines A431, HME1, A375 and SK23, so that Houttuynoid A can be used to prepare medicines for inhibiting skin cancer and has good development application prospect. The application of Houttuynoid A in medicines for treating skin cancer is disclosed for the first time, and has extremely high inhibitory activity to breast caner cells as the skeleton type belongs to a completely novel skeleton type.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid A, relate in particular to the application of Houttuynoid A in the anti-skin carcinoma medicine of preparation.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the present reasonable antitumor drug of effect clinically such as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound H outtuynoid A that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid A_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this chemical compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid A_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), belong to open first for the purposes of the Houttuynoid A that the present invention relates in preparation treatment skin carcinoma medicine, because framework types belongs to brand-new framework types, and its inhibition for skin cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously skin carcinoma obviously has significant progress.
Summary of the invention
The invention provides the application of compound H outtuynoid A in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid A in the anti-skin carcinoma medicine of preparation, and the structural formula of Houttuynoid A is shown in formula I:
The present invention finds that by external MTT anti-tumor activity evaluation Houttuynoid A also has significant inhibitory action to the growth of application on human skin JEG-3 A431, HME1, A375 and SK23, suppresses the IC of this 4 strain Growth of Cells
50Value is respectively 0.23 ± 0.02 μ M, 0.13 ± 0.03 μ M, 0.22 ± 0.07 μ M and 0.17 ± 0.06 μ M.Therefore, Houttuynoid A can for the preparation of anti-skin carcinoma medicine, have good development prospect.
The purposes of the Houttuynoid A that the present invention relates in preparation treatment skin carcinoma medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for skin cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously skin carcinoma obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid A involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid A_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound H outtuynoid A tablet involved in the present invention:
Get 20 and digest compound Houttuynoid A, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound H outtuynoid A capsule involved in the present invention:
Get 20 and digest compound Houttuynoid A, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Houttuynoid A to the growth inhibited effect of application on human skin JEG-3
1. method: the cell that is in the growth logarithmic (log) phase: application on human skin JEG-3 A431, HME1, A375 and SK23(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Houttuynoid A of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5 mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570 nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Houttuynoid A has significant inhibitory action to the growth of application on human skin JEG-3 A431, HME1, A375 and SK23.This chemical compound suppresses the IC of application on human skin JEG-3 A431, HME1, A375 and SK23 growth
50Value is respectively: 0.23 ± 0.02 μ M, 0.13 ± 0.03 μ M, 0.22 ± 0.07 μ M and 0.17 ± 0.06 μ M.
Shown that by above-described embodiment Houttuynoid A of the present invention has good inhibitory action to the growth of application on human skin JEG-3 A431, HME1, A375 and SK23.Prove that thus it is active that Houttuynoid A of the present invention has anti-skin carcinoma, can be for the preparation of anti-skin carcinoma medicine.
Claims (1)
1.Houttuynoid the application of A in treatment skin carcinoma medicine, described compound H outtuynoid A structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210418598.7A CN102872086B (en) | 2012-10-27 | 2012-10-27 | The application of Houttuynoid A in treatment skin carcinoma medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210418598.7A CN102872086B (en) | 2012-10-27 | 2012-10-27 | The application of Houttuynoid A in treatment skin carcinoma medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102872086A true CN102872086A (en) | 2013-01-16 |
| CN102872086B CN102872086B (en) | 2015-08-19 |
Family
ID=47473757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210418598.7A Expired - Fee Related CN102872086B (en) | 2012-10-27 | 2012-10-27 | The application of Houttuynoid A in treatment skin carcinoma medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102872086B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103127080A (en) * | 2012-10-25 | 2013-06-05 | 吴俊华 | Application of Aphanamixoid A in medicines curing skin cancer |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070080329A (en) * | 2006-02-07 | 2007-08-10 | 인제대학교 산학협력단 | Composition comprising the extract of houttuynia cordata for treating or prevening cancer disease |
-
2012
- 2012-10-27 CN CN201210418598.7A patent/CN102872086B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070080329A (en) * | 2006-02-07 | 2007-08-10 | 인제대학교 산학협력단 | Composition comprising the extract of houttuynia cordata for treating or prevening cancer disease |
Non-Patent Citations (1)
| Title |
|---|
| CHEN，S.D. ET AL: "Houttuynoid A-E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata", 《ORGANIC LETTERS》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103127080A (en) * | 2012-10-25 | 2013-06-05 | 吴俊华 | Application of Aphanamixoid A in medicines curing skin cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102872086B (en) | 2015-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102872089B (en) | Application of Houttuynoid E in preparing medicines for treating skin cancer | |
| CN102872086A (en) | Application of Houttuynoid A in medicines for treating skin cancer | |
| CN102872085B (en) | Application of Houttuynoid A in medicines for treating breast cancer | |
| CN102861057B (en) | Application of Houttuynoid D in skin cancer treatment medicine | |
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN102872148B (en) | Application of Houttuynoid D in medicament for treating tongue cancer | |
| CN102861079B (en) | Application of Houttuynoid B in medicine for treating skin cancer | |
| CN102872150B (en) | Application of Houttuynoid B in medicament for treating prostatic cancer | |
| CN102872070B (en) | Application of Houttuynoid C to preparing drugs for treating prostate cancer | |
| CN102872109B (en) | Application of Houttuynoid A in medicament for treating prostate cancer | |
| CN102872075A (en) | Application of Houttuynoid E in drugs for treating breast cancer | |
| CN102872149B (en) | Application of Houttuynoid B in medicament for treating cecum cancer | |
| CN102872139B (en) | Application of Houttuynoid C in drug for treating tongue cancer | |
| CN102885843B (en) | Application of Houttuynoid B in medicament for treating breast cancer | |
| CN102861052B (en) | Application of Houttuynoid A in medicine for treating ileocecum cancer | |
| CN102872110B (en) | Application of Houttuynoid D in medicament for treating breast cancer | |
| CN102872142B (en) | Application of Houttuynoid D in drug for treating ovarian cancer | |
| CN102861081A (en) | Application of Houttuynoid C in medicine for treating skin cancer | |
| CN102872088A (en) | Application of Houttuynoid D in medicines for treating nasopharyngeal carcinoma | |
| CN102895248A (en) | Application of Houttuynoid A in drugs for treating laryngocarcinoma | |
| CN102872102A (en) | Application of Houttuynoid C in medicine for treating breast cancer | |
| CN102872151A (en) | Application of Houttuynoid B in medicament for treating nasopharyngeal cancer | |
| CN103356547A (en) | Application of Sarcaboside A in preparation of drug for treating skin cancer | |
| CN102872117A (en) | Application of Houttuynoid D in medicament for treating gastric cancer | |
| CN102872125A (en) | Application of Houttuynoid C in medicament for treating cervical cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150819 Termination date: 20151027 |
|
| EXPY | Termination of patent right or utility model |